Moderate and severe dementia can benefit from donepezil

NEW research backs continuation of donepezil when patients with Alzheimer’s disease progress to moderate to severe dementia.

Please Login to Access Medical Observer

If you have an account select Login. If you are new to Medical Observer select Join.

Login Join

Author:

Rada Rouse

Clinical Content Editor

Rada is an award-winning medical journalist and a former president of the Australasian Medical Writers Association.

You will be taken to medicaljobs.com.au